- Home
- ASPC vs VERU Comparison
ASPC vs VERU Comparison
Compare ASPC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPC
- VERU
- Stock Information
- Founded
- ASPC 2024
- VERU 1971
- Country
- ASPC Hong Kong
- VERU United States
- Employees
- ASPC N/A
- VERU N/A
- Industry
- ASPC
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- ASPC
- VERU Health Care
- Exchange
- ASPC Nasdaq
- VERU Nasdaq
- Market Cap
- ASPC 82.6M
- VERU 85.5M
- IPO Year
- ASPC 2024
- VERU 1990
- Fundamental
- Price
- ASPC $10.27
- VERU $0.61
- Analyst Decision
- ASPC
- VERU Strong Buy
- Analyst Count
- ASPC 0
- VERU 2
- Target Price
- ASPC N/A
- VERU $4.00
- AVG Volume (30 Days)
- ASPC 3.2K
- VERU 2.5M
- Earning Date
- ASPC 01-01-0001
- VERU 08-07-2025
- Dividend Yield
- ASPC N/A
- VERU N/A
- EPS Growth
- ASPC N/A
- VERU N/A
- EPS
- ASPC 0.05
- VERU N/A
- Revenue
- ASPC N/A
- VERU $16,886,419.00
- Revenue This Year
- ASPC N/A
- VERU N/A
- Revenue Next Year
- ASPC N/A
- VERU N/A
- P/E Ratio
- ASPC $220.96
- VERU N/A
- Revenue Growth
- ASPC N/A
- VERU 134.43
- 52 Week Low
- ASPC $9.95
- VERU $0.45
- 52 Week High
- ASPC $10.51
- VERU $1.42
- Technical
- Relative Strength Index (RSI)
- ASPC N/A
- VERU 55.75
- Support Level
- ASPC N/A
- VERU $0.57
- Resistance Level
- ASPC N/A
- VERU $0.64
- Average True Range (ATR)
- ASPC 0.00
- VERU 0.03
- MACD
- ASPC 0.00
- VERU 0.00
- Stochastic Oscillator
- ASPC 0.00
- VERU 87.20
About ASPC A SPAC III Acquisition Corp. Class A Ordinary Shares
A SPAC III Acquisition Corp is a blank check company.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.